Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 11, keine Gesamtzahl für „when“
Suchtreffer
Begriffe & Kennungen
Dynastat · 4.5 · The effect of enzyme induction has not been studied. The metabolism of valdecoxib may increase when coadminist
Eintrag öffnenDzuveo · 4.5 · When considering the use of sufentanil in a patient taking a CNS depressant, the duration of use of the CNS de
Eintrag öffnenEarly satiety
Eintrag öffnenEdarbi · 4.8 · Description of selected adverse reactions When Edarbi was coadministered with chlortalidone, the frequencies o
Eintrag öffnenEdarbi · 4.8 · When Edarbi was coadministered with amlodipine, the frequency of peripheral oedema was increased from uncommon
Eintrag öffnenEfavirenz Teva · 4.5 · Efavirenz exposure may be increased when given with medicinal products (for example, ritonavir) or food (for e
Eintrag öffnenElebrato Ellipta · 4.5 · Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicist
Eintrag öffnenEliquis · 4.5 · 45 when coadministered with SSRIs/SNRIs, NSAIDs, ASA and/or P2Y12 inhibitors because these medicinal products
Eintrag öffnenEliquis · 4.5 · Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplat
Eintrag öffnenEliquis · 4.5 · Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplat
Eintrag öffnenEliquis · 4.5 · Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplat
Eintrag öffnenEliquis · 4.5 · Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplat
Eintrag öffnenEliquis · 4.5 · No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coad
Eintrag öffnenEliquis · 4.5 · No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coad
Eintrag öffnenEliquis · 4.5 · No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coad
Eintrag öffnenEliquis · 4.5 · No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coad
Eintrag öffnenEliquis · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
Eintrag öffnenEliquis · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
Eintrag öffnenEliquis · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
Eintrag öffnenEliquis · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
Eintrag öffnen